FTC May Be Hampered In Pursuing Actions Against Pharma In Wake Of Supreme Court Ruling
High court’s decision that FTC lacks authority to seek monetary recovery in litigation is boon for drug makers who have been subject to hefty payouts in reverse settlement and other cases brought by the commission.
You may also be interested in...
Agency staff has more freedom to launch investigations under resolutions approved at Commission’s first meeting under new chair. Mergers and rebate walls expected to be major priorities.
The report outlines the lawsuits that the Food and Drug Law Institute believes could have the greatest impacts on industries regulated by the US FDA.
During subcommittee markup, Republican members offered amendments to limit FTC’s ability to seek monetary relief for consumers. Measure has the ‘potential to be a legacy bill,’ ranking member says, indicating it may clear Congress.